Further, within the neoadjuvant trial treating HNSCC patients with BA, whole-exome sequencing data showed no relationship between TGF-β signaling gene mutations and the likelihood of a partial response [78]. This evidence concerns the gene TGFB1 and head and neck squamous cell carcinoma.